- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy in esophageal cancer
Authors
Keywords
-
Journal
Expert Review of Gastroenterology & Hepatology
Volume 10, Issue 5, Pages 595-604
Publisher
Informa UK Limited
Online
2016-02-20
DOI
10.1586/17474124.2016.1140036
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
- (2015) J. Vansteenkiste et al. ANNALS OF ONCOLOGY
- Targeted therapy in gastric cancer
- (2015) Alexandra Thiel et al. APMIS
- The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
- (2015) Dongxian Jiang et al. BMC CANCER
- A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers
- (2015) C Wu et al. BRITISH JOURNAL OF CANCER
- Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study
- (2015) Émilie Soularue et al. BULLETIN DU CANCER
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma
- (2015) Jing Tian et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight
- (2015) Giuseppe Aprile et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
- (2015) Marie Kurokawa et al. JOURNAL OF RADIATION RESEARCH
- Induction chemotherapy with cetuximab, vinorelbine–cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine–cisplatin in patients with unresectable stage III non-small cell lung cancer
- (2015) Di Liu et al. LUNG CANCER
- Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer
- (2015) Yelena Y. Janjigian et al. PLoS One
- Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051)†
- (2014) A. C. Lockhart et al. ANNALS OF ONCOLOGY
- Relationship between EGFR Over-expression and Clinicopathologic Characteristics in Squamous Cell Carcinoma of the Esophagus: A Meta-analysis
- (2014) Jun Wang et al. Asian Pacific Journal of Cancer Prevention
- Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials
- (2014) D. P. S. Sohal et al. DISEASES OF THE ESOPHAGUS
- Targeted therapies in gastroesophageal cancer
- (2014) Stefan Kasper et al. EUROPEAN JOURNAL OF CANCER
- Preoperative Chemoradiation Therapy in Combination With Panitumumab for Patients With Resectable Esophageal Cancer: The PACT Study
- (2014) Sil Kordes et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study†
- (2013) M. J. D. Prins et al. ANNALS OF ONCOLOGY
- Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
- (2013) N C Tebbutt et al. BRITISH JOURNAL OF CANCER
- Results of docetaxel plus oxaliplatin (DOCOX)±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study
- (2013) Donald Richards et al. EUROPEAN JOURNAL OF CANCER
- Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
- (2013) A.F.C. Okines et al. EUROPEAN JOURNAL OF CANCER
- Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus
- (2013) Ning-Yi Ma et al. International Journal of Clinical Oncology
- A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92
- (2013) Carlos R. Becerra et al. Journal of Thoracic Oncology
- Oesophageal carcinoma
- (2013) Arjun Pennathur et al. LANCET
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
- (2013) Thomas Crosby et al. LANCET ONCOLOGY
- Preoperative Cetuximab, Irinotecan, Cisplatin, and Radiation Therapy for Patients With Locally Advanced Esophageal Cancer
- (2013) M. S. Lee et al. ONCOLOGIST
- A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
- (2013) H. E. Uronis et al. ONCOLOGIST
- Adding Preoperative Radiotherapy Plus Cetuximab to Perioperative Chemotherapy for Resectable Esophageal Adenocarcinoma: A Single-Center Prospective Phase II Trial
- (2013) I. Ubink et al. ONCOLOGIST
- Erlotinib and Radiation Therapy for Elderly Patients with Esophageal Cancer - Clinical and Correlative Results from a Prospective Multicenter Phase 2 Trial
- (2013) Renuka Iyer et al. ONCOLOGY
- Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail
- (2013) Xue Meng et al. RADIOTHERAPY AND ONCOLOGY
- Antibody Therapeutics in Cancer
- (2013) M. X. Sliwkowski et al. SCIENCE
- Clinical significance of the expression of EGFR signaling pathway-related proteins in esophageal squamous cell carcinoma
- (2013) Jian-Cheng Li et al. TUMOR BIOLOGY
- Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial
- (2013) Liang et al. OncoTargets and Therapy
- Synchronous rectal and esophageal cancer treated with chemotherapy followed by two-stage resection
- (2013) Setsuo Utsunomiya World Journal of Clinical Cases
- Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report
- (2012) A. F. C. Okines et al. ANNALS OF ONCOLOGY
- Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas
- (2012) Isabela Martins Gonzaga et al. BMC CANCER
- Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.
- (2012) Mayra Ramos-Suzarte et al. CANCER BIOLOGY & THERAPY
- Targetting Esophageal and Gastric Cancers with Monoclonal Antibodies
- (2012) Emmanuelle Norguet et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma
- (2012) X. F. Guo et al. DISEASES OF THE ESOPHAGUS
- Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study
- (2012) Y. Zhai et al. DISEASES OF THE ESOPHAGUS
- Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas
- (2012) Tanja Trarbach et al. INVESTIGATIONAL NEW DRUGS
- Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma
- (2012) M. J. D. Prins et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe
- (2012) Jordan M. Schmitt et al. Journal of Thoracic Oncology
- Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3
- (2012) Lei Zhao et al. Journal of Translational Medicine
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors
- (2012) H. A. Burris et al. MOLECULAR CANCER THERAPEUTICS
- Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
- (2011) Z A Wainberg et al. BRITISH JOURNAL OF CANCER
- Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
- (2011) J. Qi et al. CANCER RESEARCH
- A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction
- (2011) David J. Adelstein et al. INVESTIGATIONAL NEW DRUGS
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
- (2010) S. Rao et al. ANNALS OF ONCOLOGY
- MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
- (2010) V. Cepero et al. CANCER RESEARCH
- Phase II Study of Concurrent Chemoradiation in Combination With Erlotinib for Locally Advanced Esophageal Carcinoma
- (2010) Gang Li et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- EGFR Antibodies in Colorectal Cancer: Where Do They Belong?
- (2010) Axel Grothey JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
- (2010) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
- (2010) Keith C Bible et al. LANCET ONCOLOGY
- MET molecular mechanisms and therapies in lung cancer
- (2010) Ryan E. Lawrence et al. Cell Adhesion & Migration
- Structure-Based View of Epidermal Growth Factor Receptor Regulation
- (2008) Kathryn M. Ferguson Annual Review of Biophysics
- Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
- (2008) S Rao et al. BRITISH JOURNAL OF CANCER
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More